Loading...
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
Propper, D Jones, K Anthoney, D Mansoor, Was Ford, D Eatock, M Agarwal, R Inatani, M Saito, T Abe, M
Propper, D
Jones, K
Anthoney, D
Mansoor, Was
Ford, D
Eatock, M
Agarwal, R
Inatani, M
Saito, T
Abe, M
Citations
Altmetric:
Abstract
TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas.
Description
Date
2016-10-10
Publisher
Collections
Files
Keywords
Type
Article
Citation
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. 2016, 16 (1):779 BMC Cancer